Clinical trial
A Phase I/II Open Label Multi Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
NCT03278626 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Open Label Multi Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Lead sponsor
- NYU Langone Health
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- June 27, 2017
- Completion date
- May 31, 2021
- Enrollment
- 12 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.